


ORONTO CENTRE FOR IVER DISEASE

C Kandel^{*1}, MJ Biondi^{*1,2}, R. Kozak¹, MA Zahoor^{1,2}, I Choong³, C Hislop³, J Glenn⁴, AJ Gehring^{1,2}, HLA Janssen^{1,2}, B Hansen^{1,2}, JJ Feld^{1,2}.

1. University of Toronto. 2. Toronto Centre for Liver Disease, 3. Eiger Biopharmaceuticals 4. Stanford School of Medicine. * Contributed equally to the work



Fype I Systemic vs Type III Epithelia


Background

- Interferons (IFN) are a major component of the innate antiviral immune response and produced in response to viral infection Interferons drive induction of a host of genes with antiviral and immunoregulatory properties known as interferon stimulated genes Interferons are divided based on the receptor used for signaling The Type I interferon receptor (alpha/beta) is expressed on every cell in the body whereas the Type III interferon receptor (lambda) is expressed primarily in epithelial tissues: lung, liver, intestine with limited expression on inflammatory cells
- Interferon lambda has been shown to be important in controlling respiratory viral infections (eg. influenza) with a lower chance of stimulating a systemic response such as cytokine storm syndrome - Interferon lambda induction is impaired in COVID-19 but interferon lambda treatment suppresses SARS-CoV-2 in cell culture and animal models
- Peginterferon lambda has been used in >3000 patients with HBV and HCV infections with similar antiviral activity but better side effect profile than interferon alpha

We therefore hypothesized that treatment with interferon lambda would be effective for treatment of mild to moderate COVID-19

Aims

Il randomized, double blind, placebo-controlled, A phase multicenter trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19



Pre-specified analysis of primary endpoint controlling for baseline viral load

Inclusion Criteria:

- 18-75 yo
- within 7 d of symptom onset or first + swab if asymptomatic

Exclusion Criteria:

- Need for hospital admission
- Immunosuppression
- Pregnancy
- Medical conditions potentially worsened by PegIFN lambda seizure disorder, autoimmune disease, active retinal disease, severe psychiatric disease
- Other significant comorbidity that would preclude use of PegIFN lambda

Statistical analysis

- ITT analysis missing counted as positive
- Proportion positive at Day 7 (crude and controlled for baseline viral load)
- Factors associated with clearance by logistic regression

Laboratory Analysis

- Quantitative PCR for SARS-CoV-2 using plasmid-derived cDNA standards
- Anti-SARS-Co-V2 antibodies IgG Diasorin


Peginterferon Lambda for the treatment COVID-19

Results


Table 1. Patient Demographic and Disease Characteristics

		01					
		IFN Lambda (n=30)	Placebo (n=30)			IFN Lambda (n=30)	Placeb (n=30)
Sex	Male Female	12 (40%) 18 (60%)	13 (43%) 17 (57%)	Duration of Symptoms	Days <i>,</i> Mean (SD)	4.3 (1.7)	4.7 (1.7
Age	Years (SD)	44 (13)	42 (13)	Time from test	Days, Mean (SD)	3.2 (1.1)	3.3 (1.2)
Race	White	15 (50%)	16 (53%)	to Day 0			
	Black Asian		Asymptomatic		5 (18%)	6 (21%)	
	Other	6 (18%)	2 (6%)				
Co- morbidity	DM/CHF/HTN	5 (17%)	4 (13%)			IFN Lambda (n=30)	Placebo (n=30)
BMI	Mean (SD)	27.3 (5.2)	26.1 (4.2)	Viral load baseline, mean (SD) log copies/mL		6.2 (3.1)	4.9 (3.7)
BMI Category	<25 25-30 >30	9 (30%) 15 (50%) 6 (20%)	11 (37%) 13 (43%) 6 (20%)	Viral load undetectable at BL, n(%)		5 (17%)	10 (33%)
IFNL4	Non-TT	18 (60%)	16 (57%)			19 (63%)	16 (53%)
genotype	TT	12 (40%	12 (43%)			0/27 (0%)	5/24 (21%

Figure 2. Mean SARS-CoV-2 viral load over time and mean decline viral load





The mean decline in viral load was greater with peginterferon lambda treatment than control started at Day 3, with a maximal difference of 2.42 log copies/mL greater than placebo at Day 7 post-dosing.



Baseline viral load was strongly associated with clearance by Day 7. After controlling for baseline viral load, peginterferon lambda treatment was associated with clearance by Day 7 (primary endpoint).

Figure 3. Probability of clearance with peginterferon lambda vs placebo as a function of baseline viral load






At low baseline viral load, clearance by Day 7 is likely in both groups. With every log increase in baseline viral load, the odds of clearance by Day 7 with peginterferon lambda vs placebo increases.

Baseline viral load strongly associated with probability of clearance at Day 7 – OR 0.64 (0.40-0.85, p=0.0009)

aseline viral	load:
	Odds Ratio (95% Cl)
vs Placebo	4.12 (1.15-16.7), p=0.029
eline	0.69 (0.51-0.87), p=0.001







OntarioTogether

COVID-19 ACTION FUND

Funding provided by grants from: • University of Toronto - Toronto COVID Action Committee • Ontario Together **Medication provided** by Eiger Biopharmaceuticals